Are the Clinical Presentations (Phenotypes) of Gitelman's and Bartter's Syndromes Gene Mutations Driven by Their Effects on Intracellular pH, Their "pH" Enotype?

被引:6
作者
Calo, Lorenzo A. [1 ]
Davis, Paul A. [2 ]
机构
[1] Univ Padua, Dept Med, Nephrol Dialysis & Transplantat Unit, I-35128 Padua, Italy
[2] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA
关键词
Gitelman's syndrome; Bartter's syndrome; gene mutations; glycosylation; endosome pH; phenotype; ACE2; Ang; 1-7; RENIN-ANGIOTENSIN SYSTEM; KIDNEY-DISEASE; ACE2; MECHANISMS; CLCNKB; INHIBITION; EXPRESSION; CYSTINOSIS; REGULATOR; APELIN;
D O I
10.3390/ijms21165660
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gitelman's syndrome (GS) and Bartter's syndrome (BS) are rare inherited salt-losing tubulopathies whose variations in genotype do not correlate well with either clinical course or electrolyte requirements. Using GS/BS patients as nature's experiments, we found them to be a human model of endogenous Ang II antagonism with activated Renin-Angiotensin System (RAS), resulting in high Ang II levels with blunted cardiovascular effects. These patients are also characterized by increased and directly correlated levels of both Angiotensin Converting Enzyme 2 (ACE2) and Ang 1-7. Understanding the myriad of distinctive and frequently overlapping clinical presentations of GS/BS arises remains challenging. Efforts to find a treatment for COVID-19 has fueled a recent surge in interest in chloroquine/hydroxychloroquine and its effects. Of specific interest are chloroquine/hydroxychloroquine's ability to inhibit SARS-CoV infection by impairing ACE2, the SARS-CoV2 entry point, through terminal glycosylation via effects on TGN/post-Golgi pH homeostasis. Several different studies with a GS or a BS phenotype, along with a nonsyndromic form of X-linked intellectual disability linked to a mutated SLC9A7, provide additional evidence that specific gene defects can act via misregulation of TGN/post-Golgi pH homeostasis, which leads to a common mechanistic basis resulting in overlapping phenotypes. We suggest that linkage between the specific gene defects identified in GS and BS and the myriad of distinctive and frequently overlapping clinical findings may be the result of aberrant glycosylation of ACE2 driven by altered TGN/endosome system acidification caused by the metabolic alkalosis brought about by these salt-losing tubulopathies in addition to their altered intracellular calcium signaling due to a blunted second messenger induced intracellular calcium release that is, in turn, amplified by the RAS system.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 43 条
  • [1] Neutralization of pH in the Golgi apparatus causes redistribution of glycosyltransferases and changes in the O-glycosylation of mucins
    Axelsson, MAB
    Karlsson, NG
    Steel, DM
    Ouwendijk, J
    Nilsson, T
    Hansson, GC
    [J]. GLYCOBIOLOGY, 2001, 11 (08) : 633 - 644
  • [2] Sustained Cardiovascular Actions of APJ Agonism During Renin-Angiotensin System Activation and in Patients With Heart Failure
    Barnes, Gareth D.
    Alam, Shirjel
    Carter, Gordon
    Pedersen, Christian M.
    Lee, Kristina M.
    Hubbard, Thomas J.
    Veitch, Scott
    Jeong, Herim
    White, Audrey
    Cruden, Nicholas L.
    Huson, Les
    Japp, Alan G.
    Newby, David E.
    [J]. CIRCULATION-HEART FAILURE, 2013, 6 (03) : 482 - +
  • [3] Basque J, 2008, CAN J PHYSIOL PHARM, V86, P606, DOI 10.1139/y08-063
  • [4] Bastug F, 2018, IRAN J KIDNEY DIS, V12, P61
  • [5] Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure
    Basu, Ratnadeep
    Poglitsch, Marko
    Yogasundaram, Haran
    Thomas, Jissy
    Rowe, Brian H.
    Oudit, Gavin Y.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (07) : 805 - 819
  • [6] BERIO A, 1978, MINERVA PEDIATR, V30, P1825
  • [7] Letter: ACE2, Rho kinase inhibition and the potential role of vitamin D against COVID-19
    Bertoldi, Giovanni
    Gianesello, Lisa
    Calo, Lorenzo A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (03) : 577 - 578
  • [8] Electrocardiogram with prolonged QT interval in Gitelman disease
    Bettinelli, A
    Tosetto, C
    Colussi, G
    Tommasini, G
    Edefonti, A
    Bianchetti, MG
    [J]. KIDNEY INTERNATIONAL, 2002, 62 (02) : 580 - 584
  • [9] Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
    Blanchard, Anne
    Bockenhauer, Detlef
    Bolignano, Davide
    Calo, Lorenzo A.
    Cosyns, Etienne
    Devuyst, Olivier
    Ellison, David H.
    Frankl, Fiona E. Karet
    Knoers, Nine V. A. M.
    Konrad, Martin
    Lin, Shih-Hua
    Vargas-Poussou, Rosa
    [J]. KIDNEY INTERNATIONAL, 2017, 91 (01) : 24 - 33
  • [10] Cal L.A., 2019, BARTTER GITELMAN SYN, V3, P713, DOI [10.1016/B978-0-12-812199-3.65335-5, DOI 10.1016/B978-0-12-812199-3.65335-5]